Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice.
Tuberoinfundibular dopamine tonically inhibits PRL expression and secretion from the pituitary gland by the activation of dopamine D2 receptors (D2R) localized on lactotrophs. Mutant female mice that lack D2Rs have persistent hyperprolactinemia but also develop extensive hyperplasia of pituitary lactotrophs and peliosis of the adenohypophysis at 9 to 12 months of age, while age-matched male D2R-deficient mice have no morphologic adenohypophysial lesion. We now report that both female and male D2R-deficient mice 17 to 20 months of age develop pituitary lactotroph adenomas. Of 12 aged female mice examined, all developed monohormonal PRL-immunoreactive neoplasms that had a characteristic juxtanuclear Golgi pattern of PRL staining and loss of the reticulin fiber network. Several of these adenomas were 50-fold larger than normal glands with marked suprasellar extension and invasion of brain but no gross evidence of distant metastases. They also had striking peliosis that was more marked than the lesion seen in the hyperplastic pituitaries of the younger females. These findings demonstrate that a chronic loss of neurohormonal dopamine inhibition promotes the hyperplasia-neoplasia sequence in adenohypophysial lactotrophs. Our results are analogous to previous data indicating that protracted stimulation of adenohypophysial cells by hormones or growth factors results in proliferation with initial hyperplasia followed by the development of neoplasia. Six aged male D2R-deficient mice had slightly enlarged anterior pituitaries similar in size to normal female glands. However, each case exhibited multifocal, microscopic lactotroph adenomas with strong nuclear immunoreactivity for estrogen receptors and Pit-1 transcription factor. The unexpected development of adenomas in males without preexisting or concomitant hyperplasia suggests that prolonged loss of dopamine inhibition may also cause neoplasia by distinct cellular mechanisms in male and female animals.
Asa
S L
SL
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada. sasa@mtsinai.on.ca
Kelly
M A
MA
Grandy
D K
DK
Low
M J
MJ
D000324:Adrenocorticotropic Hormone / Q000032:analysis; D000818:Animals; D005260:Female; D005640:Follicle Stimulating Hormone / Q000032:analysis; D013006:Growth Hormone / Q000032:analysis; D006965:Hyperplasia; D006966:Hyperprolactinemia / Q000209:etiology; D007150:Immunohistochemistry; D007986:Luteinizing Hormone / Q000032:analysis; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D010902:Pituitary Gland / Q000737:chemistry / Q000473:pathology; D010903:Pituitary Gland, Anterior / Q000473:pathology; D010911:Pituitary Neoplasms / Q000209:etiology* / Q000473:pathology; D015175:Prolactinoma / Q000209:etiology* / Q000473:pathology; D017448:Receptors, Dopamine D2 / Q000172:deficiency* / Q000502:physiology; D013972:Thyrotropin / Q000032:analysis
D017448:Receptors, Dopamine D2; D000324:Adrenocorticotropic Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; D013006:Growth Hormone